Abstract
The in vitro activities of ceftolozane-tazobactam, meropenem, and metronidazole were determined against anaerobic organisms isolated from patients with complicated intraabdominal infections (cIAI) in global phase III studies. Ceftolozane-tazobactam activity was highly variable among different species of the Bacteroides fragilis group, with MIC90 values ranging from 2 to 64 μg/ml. More-potent in vitro activity was observed against selected Gram-positive anaerobic organisms; however, small numbers of isolates were available, and, therefore, the clinical significance of these results is unknown. Variable activity of ceftolozane-tazobactam against anaerobic organisms necessitates use in combination with metronidazole for the treatment of cIAI.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anaerobiosis
-
Anti-Bacterial Agents / therapeutic use*
-
Bacteroides / drug effects
-
Bacteroides / isolation & purification
-
Bacteroides Infections / drug therapy*
-
Bacteroides Infections / microbiology
-
Bacteroides fragilis / drug effects
-
Bacteroides fragilis / isolation & purification
-
Cephalosporins / therapeutic use*
-
Drug Therapy, Combination / methods
-
Gram-Positive Bacteria / drug effects
-
Gram-Positive Bacteria / isolation & purification
-
Gram-Positive Bacterial Infections / drug therapy*
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Intraabdominal Infections / drug therapy*
-
Intraabdominal Infections / microbiology
-
Metronidazole / therapeutic use*
-
Microbial Sensitivity Tests
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / therapeutic use
-
Tazobactam
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
ceftolozane, tazobactam drug combination
-
Metronidazole
-
Penicillanic Acid
-
Tazobactam
Grants and funding
This study was funded by Merck & Co., Inc., Kenilworth, NJ, USA.